NasdaqGM - Nasdaq Real Time Price USD

Corvus Pharmaceuticals, Inc. (CRVS)

4.4300
+1.0800
+(32.24%)
At close: May 9 at 4:00:00 PM EDT
4.4304
+0.00
+(0.01%)
After hours: May 9 at 7:59:55 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
27,548
27,548
23,407
32,565
38,630
Operating Income
-27,548
-27,548
-23,407
-32,565
-38,630
Net Non Operating Interest Income Expense
1,824
1,824
1,584
654
-15
Other Income Expense
-36,569
-36,569
-5,206
-9,396
-4,596
Pretax Income
-62,293
-62,293
-27,029
-41,307
-43,241
Net Income Common Stockholders
-62,293
-62,293
-27,029
-41,307
-43,241
Diluted NI Available to Com Stockholders
-62,293
-62,293
-27,029
-41,307
-43,241
Basic EPS
-0.99
-1.02
-0.56
-0.89
-1.03
Diluted EPS
-0.99
-1.02
-0.56
-0.89
-1.03
Basic Average Shares
56,147.4070
60,985.1650
48,025.2740
46,553.5110
41,854.1100
Diluted Average Shares
56,147.4070
60,985.1650
48,025.2740
46,553.5110
41,854.1100
Total Operating Income as Reported
-27,548
-27,548
-23,407
-32,565
-38,630
Total Expenses
27,548
27,548
23,407
32,565
38,630
Net Income from Continuing & Discontinued Operation
-62,293
-62,293
-27,029
-41,307
-43,241
Normalized Income
-28,921
-28,921
-27,029
-41,329
-43,241
Interest Income
1,824
1,824
1,584
654
--
Interest Expense
--
--
--
--
15
Net Interest Income
1,824
1,824
1,584
654
-15
EBIT
-27,548
-27,548
-23,407
-32,565
-38,630
EBITDA
-27,463
-27,463
-23,256
-32,198
-38,170
Reconciled Depreciation
85
85
151
367
460
Net Income from Continuing Operation Net Minority Interest
-62,293
-62,293
-27,029
-41,307
-43,241
Total Unusual Items Excluding Goodwill
-33,372
-33,372
0
22
0
Total Unusual Items
-33,372
-33,372
0
22
0
Normalized EBITDA
5,909
5,909
-23,256
-32,220
-38,170
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 3/23/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CTMX CytomX Therapeutics, Inc.
0.9284
-14.83%
 
CAMP CAMP4 THERAPEUTICS CORPORATION
2.1300
-0.47%
 
KTTA Pasithea Therapeutics Corp.
0.8310
-13.44%
 
TOVX Theriva Biologics, Inc.
0.5299
-17.61%
 
PLRZ Polyrizon Ltd.
0.3747
-36.58%
 
NCNA NuCana plc
0.0420
-59.18%
 
IMMP Immutep Limited
1.8500
-0.54%
 
GLMD Galmed Pharmaceuticals Ltd.
1.2400
-0.80%
 
SPRC SciSparc Ltd.
0.3443
+0.53%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5272
-7.70%